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s u m m a r y
Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite
its clinical relevance, metastasis remains the most poorly elucidated aspect of carcinogenesis.
The biological mechanisms leading to bone metastasis establishment have been referred as
“vicious circle”, a complex network between cancer cells and the bone microenvironment. This
review is aimed to underline the new molecular targets in bone metastases management other
than bisphosphonates. Different pathways or molecules such as RANK/RANKL/OPG, cathepsin K,
endothelin-1, Wnt/DKK1, Src have recently emerged as potential targets and nowadays preclinical
and clinical trials are underway. The results from those in the advanced clinical phases are
encouraging and underlined the need to design large randomised clinical trials to validate these
results in the next future.
Targeting the bone by preventing skeletal related events (SREs) and bone metastases has major
clinical impact in improving survival in bone metastatic patients and in preventing disease relapse
in adjuvant setting.
© 2010 Elsevier Ltd. All rights reserved.
Introduction: Bone metastases – from the niche to
“vicious circle”
Bone metastases are the major cause of morbidity, and ultimately
mortality, in cancer patients. 1 Despite its clinical relevance, metas-
tasis remains the most poorly elucidated aspect of carcinogenesis.
The establishment of bone metastasis is driven by a complex
network between cancer cells and the bone microenvironment
which is classically referred as “vicious circle”. At the earliest
steps, prior to the establishment of the vicious cycle, cancer cells
and their associated stromal cells alter the marrow environment
and prime it by secreting a magnitude of growth factors and
cytokines. Bone marrow-derived hematopoietic progenitors that
express vascular endothelial growth factor receptor 1 (VEGFR1+)
mobilize in response to the unique pattern of growth factors and
chemokines produced by the primary tumor. Their arrival in distant
sites acts on the local microenvironment, termed the “premetastatic
niche,” which dictate the proﬁle of metastatic spread. 2
Importantly, examination of bone marrow metastases identiﬁed
different determinants which might predict for later distant relapse.
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Identifying which of these cells have higher metastatic potential is
of major clinical signiﬁcance and therapeutic approach.
In order to form bone metastasis, cancer cells ﬁrst have to
metastasize to the bone marrow which is mainly composed of
hematopoietic stem cells (HSCs) residing in two different biological
structures known as osteoblastic and vascular niches.
The “osteoblastic niche” is mainly formed by osteoblasts lining
at endosteal bone surface and providing a quiescent environment
for HSCs maintenance and expansion into different hematopoietic
lineages.
Whereas, the vascular niche, identiﬁed in association with
fenestrated endothelium of sinusoids, drives HSCs transendothelial
migration via endothelium-derived factors priming.
Communications between osteoblasts as well as other tumour
stromal cells and HSCs are mainly driven via chemoattractive factors
such as the stromal-derived factor 1 (SDF-1) on stromal cells and
its receptor CXCR4 on HSCs. 3
In addition, a cancer-related disruption of the homeostatic RANK-
RANKL loop between osteoclasts and osteoblasts occurs. Metastatic
prostate carcinomas can secrete high amounts of the RANKL
inhibitor osteoprotegerin, thereby attenuating osteoclastic reactions
during metastasis. 4 Conversely, osteolytic cancer cells can secrete
proteases that cleave RANKL into a more active form, thereby
activating the osteoclasts. 5
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Fig. 1. Vicious circle pathways and/or molecules potential candidates in targeting
bone metastases.
Moreover, because bone is a rich source of matrix-embedded
growth factors such as IGF and TGF-b, these cytokines are
released upon osteolysis and act upon the invading tumor cells
to promote the induction of osteoclast-promoting factors. This
positive feedback loop, referred to as “the vicious cycle of
osteolytic bone metastasis,” may indeed be the driving force for
the selection of osteolytic mechanisms during the development of
bone metastases. 6
It is well known amino-bisphosphonates represent the standard
treatment for bone metastasis. This class of compounds, and
particularly zoledronic acid, has been shown to display antitumor
effects, direct and indirect, by interfering with a variety of cells such
as tumor cells, osteoclasts, HCSs, MDCS, gamma delta T cells and
other immune cells and thus to inhibit the vicious cycle at different
levels.
This review is aimed to summarized the new molecular targets
in bone metastases management other than bisphosphonates.
Different pathways or molecules such as RANK/RANKL, cathepsin K,
endothelin 1, Wnt/DKK1, Src, etc have recently emerged as potential
candidates in establishing and development of bone metastasis
(Fig. 1). Nowadays preclinical and clinical trials are evaluating the
possibility to therapeutically target these pathways.
RANK/RANKL/OPG pathway
Receptor Activator of nuclear Factor-kB Ligand (RANKL), the
Receptor Activator of Nuclear Factor-kB (RANK) and the decoy
Receptor Osteoprotegerin (OPG) are members of the TNF and TNF-
receptor superfamily able to induce proliferation, differentiation,
activation and apoptosis of osteoclastic cells. Bone remodelling
is mediated by the interaction among RANKL expressed on the
osteoblasts, RANK expressed on the osteoclast surface and OPG,
the decoy receptor for RANKL that prevents osteoclast activation.
Stromal osteoblast cells support osteoclast differentiation by
their ability to secrete IL-6 and RANKL, in response to PTH,
1,25-hydroxyvitamin D3, and PGE2. 7 The interaction between
RANK/RANKL begins with the stimulation of RANK by RANKL
promoting proliferation, differentiation and survival of osteoclast
precursors and activation of mature osteoclasts. OPG, interacting
with RANKL, counteracts these effects on osteoclasts.
Thus, RANKL/OPG levels determine bone resorption.
For this biological effect, RANK/RANKL/OPG pathway displays
a key role in the growth of bone metastases: RANKL activates
osteoclast-mediated bone resorption with a consequent release
of matrix growth factors, like Tumor Growth Factor-b (TGF-b)
and platelet-derived growth factor (PDGF). The release of these
factors can further induce the growth of tumor cells establishing
a positive feedback mechanism. 8 Moreover, cytokines, chemokines,
growth factors and hormones derived from tumor cells upregulate
RANKL through parathyroid hormone-related peptide (PTHrP),
downregulating OPG. 9 Increasing evidences show a direct role of
RANK/RANKL interaction in bone metastases development (“vicious
circle”). RANK not only is expressed on osteoclasts, but also
on cancer cells. 10 Preclinical evidences on animal models of
osteolytic metastases reported targeting RANK/RANKL pathway lead
to tumoral growth inhibition with osteolysis reduction.
Denosumab
Denosumab (AMG 162) is a noncytotoxic IgG2 monoclonal antibody
with an extremely high afﬁnity for human RANKL and a long half-
life, which permits less frequent dosing. 11 It was developed to
treat patients with skeletal pathologies mediated by osteoclasts,
such as bone metastasis, multiple myeloma, and cancer treatment-
induced bone loss (CTIBL). On the basis of preclinical evidences,
many clinical trials were conducted to investigate denosumab in
metastatic bone disease. Speciﬁcally, we are waiting for the ﬁnal
results of the three ongoing clinical trials evaluating denosumab
versus ZA in metastatic breast cancer, prostate cancer as well as
advanced solid tumors and multiple myeloma. Speciﬁcally at ECCO
2009 Stopeck et al. presented the ﬁrst results regarding the Phase III
study evaluating denosumab versus zoledronic acid (ZA) in breast
cancer. They demonstrated that denosumab was superior to ZA and
reduced the risk of a ﬁrst on-study SRE by 18% (HR: 0.82, 95% CI:
0.71, 0.95; P value was less than 0.0001 for noninferiority and equal
to 0.01 for superiority study) and of ﬁrst and subsequent SRE by 23%
on multiple event analysis (HR: 0.77; 95% CI: 0.66, 0.89; P = 0.001). 12
Also the Phase III study evaluating denosumab versus ZA in other
solid tumors plus multiple myeloma showed denosumab was not
inferior compared with ZA for delaying the time to the ﬁrst on-
study SRE (HR: 0.84, 95% CI: 0.71, 0.98) (statistically signiﬁcant
for non inferiority p < 0.0007). The time to ﬁrst SRE and the time
to ﬁrst-and-subsequent SRE was also numerically greater but not
statistically superior compared to ZA (HR: 0.90, 95% CI: 0.77, 1.04). 13
At ASCO 2010 the results of the trial evaluating denosumab vs ZA in
bone metastases from advanced cancer or multiple myeloma were
presented. The time to ﬁrst SRE or hypercalcemia of malignancy
was signiﬁcantly longer in the denosumab group (HR: 0.83 [95% CI:
0.71, 0.97], p = 0.02) as was time to ﬁrst radiation to bone (HR: 0.78;
95% CI: 0.63, 0.97, p = 0.03). 14 At ASCO 2010 the study evaluating
denosumab compared with ZA for the treatment of bone metastases
in patients with castration-resistant prostate cancer was presented.
Denosumab signiﬁcantly delayed the time to ﬁrst on-study SRE
compared with ZA, (HR: 0.82; 95% CI: 0.71, 0.95; p = 0.008.) The
median time to ﬁrst on-study SRE was 20.7 mo denosumab vs.
17.1 mo ZA. Denosumab also signiﬁcantly delayed the time to ﬁrst
and subsequent on-study SRE (multiple event analysis) (HR: 0.82;
95% CI: 0.71, 0.94; p = 0.004). 15
Endothelin pathway
The Endothelins (ET) are peptides containing 21 amino acids
produced by a variety of normal cells, such as endothelial cells,
vascular smooth muscle cells and various epithelial tissues. The
endothelin family comprises four isoforms ET-1–4 (the most
recently identiﬁed). Presently, ET-1 is the most clinically relevant
isoform. The conversion to the active ET-1 form, after proteolytic
cleavage of its inactive precursor, is the main regulatory step in
controlling ET-1 levels within the body. Endothelins exert their
effects by binding to two distinct G protein-coupled receptors,
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designed as ETAR and ETBR, with different afﬁnity for the
two receptors. Most importantly, the signaling events linked
to ETRs activation induce divergent intracellular effects when
mediated by the ETAR or ETBR activation. Moreover, different
cell types associated within solid tumors (such as tumor cells,
ﬁbroblats, macrophage and endhotelial cells) overexpress ET1 and
its receptors. ET-1 exerts direct effects on cancer cells by acting
through ETB and ETA receptors. Activation of ETB receptor by ET-1
induces apoptosis in human cancer cell lines while activation of
ETA receptor drives cancer cell growth and proliferation. ET-1 exerts
also indirect effects on tumor cells. In cancers, ET-1 exerts a tumor-
promoting action through direct angiogenic effects on endothelial
cells. ETA receptor expressed on endothelial cells and activated by
ET-1 stimulates VEGF production by endothelial cells leading to
increased tumor angiogenesis. 16 ET-1 also stimulates osteoblasts
proliferation in the bone marrow via MAPK phosphorylation and
decreases osteoclastic bone resorption and motility.
In the bone microenvironment, ET-1 released from prostate
bone metastases activates ETRA on osteoblasts leading to their
proliferation and to bone density increase. Moreover, proliferating
osteoblasts release growth factors which stimulate survival and
growth of tumour cells in the bone microenvironment.
The involvement of ET1 in the hallmarks of cancer identify ET axis
as a potential therapeutic target. Blocking the ETA receptor could
inhibit osteoblastic bone growth and proliferation of metastases.
Atrasentan is an inhibitor of the ET-A receptor that has been shown
to block formation of osteoblastic metastases in mice. In a placebo-
controlled phase II trial in men with asymptomatic hormone-
refractory prostate metastatic cancer atrasentan signiﬁcantly
delayed the time to disease progression compared with placebo. 17
In a subsequent placebo-controlled phase III trial in men with
metastatic prostate cancer, atrasentan (10mg/day) did not reduce
the risk of disease progression and cancer-induced bone pain
neither an overall survival beneﬁt was detected. 18 Recently, a
Phase 2 study to investigate the safety and efﬁcacy of the speciﬁc
ETAR antagonist ZD4054 in patients with metastatic hormone-
resistant prostate cancer who were pain free or mildly symptomatic
for pain was carried out. Patients were randomized into 3 groups
to receive once-daily oral tablets of ZD4054 10mg, or 15mg, or
placebo. The primary end point of time to progression was not
achieved in this study, but an improvement was seen in overall
survival in both active treatment arms. 19 Zibotentan (ZD4054) is an
oral, speciﬁc ETA receptor antagonist. This drug is currently under
clinical evaluation through a program consisting of three random-
ized double-blind trials called ENTHUSE (ENdoTHelin A USE) M0,
M1 and M1c. ENTHUSE M0 (Study 0015, ClinicalTrials.gov identiﬁer
NCT00626548) is enrolling patients with HRPC with increasing PSA
levels but no evidence of metastatic spread.
Patients will be accrued and randomized to zibotentan or placebo.
Primary endpoints are overall survival, progression-free survival,
deﬁned as the time to appearance of metastases. Secondary
endpoints include safety and tolerability, PSA levels and health-
related quality of life. ENTHUSE M1 (Study 0014, ClinicalTrials.gov
identiﬁer NCT00554229), investigates zibotentan in HRPC patients
with asymptomatic or mildly symptomatic metastases for whom
chemotherapy is not yet appropriate randomized to zibotentan
or placebo. The primary endpoint is overall survival; secondary
endpoints include progression-free survival, safety and tolerability,
skeletal events and bone metastases, PSA levels, and health-
related quality of life. ENTHUSE M1c (Study 0033, ClinicalTri-
als.gov identiﬁer NCT00617669) HRPC patients with conﬁrmed
symptomatic metastases will be randomized to receive zibotentan
with docetaxel or docetaxel alone. The primary endpoint is overall
survival. Secondary endpoints include progression-free survival,
PSA levels, safety and tolerability, and the effect of treatment on
skeletal events.
Cathepsin K pathway
Cathepsins are a class of globular lysosomal proteases that belong
to the papain-like cysteine protease family. During the last 10 years
Cathepsin K (CathK) has been the focus of increasing attention.
It is expressed in a wide variety of tissues including the bone
in which appears to be the most abundant and speciﬁc cysteine
protease expressed by osteoclasts and osteoclast-like cells (giant
multinucleated cells). Other cells within the bone milieu (e.g.
osteoblasts and osteocytes) express cathepsin K although its role
in these cells is not well known.
Cathepsin K represents the key enzyme responsible for
osteoclastic bone resorption actively participating in the process
of bone turnover. This cysteine protease plays a key role in bone
matrix degradation and appears to be a limiting step in osteoclastic
bone resorption. 20
The well established role of cathK in bone resorption makes it
an attractive therapeutic target in the treatment of those disorders
involving bone loss, such as osteoporosis and bone metastasis.
Different cancers express cathepsin K including prostate and
breast cancers both of which have a high tendency to metastasize
to bone. 21 Until now, a role for cathepsin K in bone metastasis has
been mainly attributed to its ability to effectively degrade native
collagen I, a process necessary for the expansion of tumour within
the bone.
These observations suggest that inhibition of cathepsin K may
disrupt two processes essential to the development of bone
metastases: cancer cell invasion and osteoclast-mediated bone
resorption. Experimental data on animal tumor models have shown
inhibitors of cathepsin K effectively suppress bone resorption. 22
From this evidence, several small-molecule inhibitors of cathepsin K
have been developed and will enter soon phase 1 experimental
validation.
In vivo proof of concept study designed for treatment of osteolysis
and tumor growth in metastatic bone disease, cathepsin K inhibitor
(L-006235) showed to reduce the size of osteolytic lesions by 66%
when administered 18 days after tumor cell inoculation and 61%
when administrated at the same time as tumor cell inoculation. 23
Moreover, sequential treatment L006235 (30 and 100) plus
zoledronic acid (12ug/kg) demonstrated additive efﬁcacy in terms
of protection from osteolysis and tumor volume.
Due to its selectivity, Odanacatib is the only cathepsin k inhibitor
in clinical development. 24 A Phase II controlled study on women
with breast cancer metastatic to bone randomized to receive daily
administration of odanacatib (5mg) or a single 4mg IV dose
of zoledronic acid showed bone remodeling markers reduction
(urinary NTx) after 4 weeks treatment. 25
SRC pathway
The proto-oncogene Src (encoded by the c-src gene) is a non-
receptor, membrane-associated tyrosine kinases that belongs to Src
family kinases.
Src is widely express, the majority of cell types display low levels
of it while some others such as mature osteoclasts express high
levels of it.
Src displays multiple functions both in physiological and
pathological processes such as cell proliferation, migration, differ-
entiation, survival angiogenesis, tumorigenesis and inﬂammation.
In osteoclasts, Src is activated following integrin binding after cells
attach to bone matrix to start the resorptive process and also
after RANKL binding to RANK. Src signaling is a key pathway
during normal, healthy bone turnover and has also been shown
to be essential for the normal organization of the osteoclasts
cytoskeleton. 26 With regard to bone remodeling Src coordinates
both osteoclast and osteoblast activities: it positively regulates
osteoclasts survival and resorbing activity, and conversely, Src
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may negatively regulate osteoblast maturation through inhibition
of runt-related transcription factor 2 (Runx2) regulated genes. 27
Thus, Src kinase is essential for osteoclast activation and
osteoblast inhibition. During tumorigenesis Src aberrantly activate
certain physiological processes thereby supporting tumor growth,
metastatization and tissue invasion. Moreover, an increased
expression and activity of Src have been described in a wide variety
of tumor types including prostate, colon and breast cancer. 28 The
Src role in patients with metastatic bone disease is of particular
importance given its involvement in both bone turnover and
bone metastases formation. An increased Src-mediated osteoclastic
activity leads to an uncontrolled release of growth factors (such as
TGF-b, IGF I, II, PDGF) into the bone microenvironment due to the
enhanced bone resorption process. Evidence for the importance of
Src in the formation of bone metastases comes from studies in mice
showing how Src inhibition or disruption results in a diminished
capacity of bone metastases development.
Increased Src activity is known to correlate with tumor
progression, with the highest activity in metastatic tissue. Pre-
clinical studies have demonstrated that decreased c-Src expression
enhances osteoblast proliferation and bone formation. 29 Different
Src inhibitors have been developed by the pharmaceutical industry
with several of them in advanced clinical trials.
Saracatinib (AZD0530) is an orally active small-molecular-weight
inhibitor of c-Src and BCR-Abl. Its efﬁcacy in bone resorption
has been demonstrated in two phase I clinical trials. 30 Dasatinib,
saracatinib, and bosutinib are currently being investigated in early
clinical trials in patients with prostate or breast cancer. Results have
also been reported from a phase 1/2 study of dasatinib administered
in combination with docetaxel in patients with progressive CRPC.
Bone markers (uNTX, BAP) decrease, a PSA decline, and RECIST
partial response was registered. 31
In a phase 2 trial of saracatinib (175mg daily) in patients with
advanced CRPC, treatment was well tolerated and ﬁve patients
had a slight reduction in PSA. However, bone effects were not
reported. 32 In a small study of patients with multiple myeloma,
dasatinib had effects on markers of osteoclast but not osteoblast
function. 33
Several clinical trials are ongoing with SRC inhibitors to evaluate
bone markers as a speciﬁed endpoint in addition to tumor
responses, including the randomized phase 3 trial of dasatinib
in combination with docetaxel (NCT00744497). Trials in breast
cancer include: two randomized phase 2 studies of the aromatase
inhibitors exemestane (NCT00767520) or letrozole (NCT00696072)
administered with or without dasatinib; a randomized phase 2
study of fulvestrant (estrogen receptor antagonist) with or without
dasatinib (NCT00566618); a phase 1/2 study of dasatinib in
combination with zoledronic acid (NCT00566618); and a phase 2
of dasatinib administered either once or twice daily in patients
with breast cancer and bone metastases (NCT00410813). Saracatinib
effects on bone markers will be evaluated in a randomized
phase 2 trial versus zoledronic acid in patients with prostate or
breast cancer (NCT00558272) and a phase 2 study of patients
with metastatic hormone receptor-negative or locally advanced
unresectable breast cancer (NCT00559507). Randomized phase 2
trials of exemestane (NCT00793546) or letrozole (NCT00880009)
with or without bosutinib are either planned or ongoing,
respectively, although it is currently unclear if bone markers will
be assessed.
WNT pathway
Wnt are cysteine-rich, secreted glycoproteins involved in embryonic
development, tissue induction, and axial polarity. Wnt ligands
activate several different receptor-mediated signal transduction
pathways, together with that mediated by b-catenin, known as
the canonical pathway. The Wnt pathway has been demonstrated
to be a major signaling pathway in osteoblasts In the presence
of Wnt ligand, Wnt binds to the receptor Fz and to the co-
receptor LRP-5/6, leading to Dvl activation, which results in the
disassociation of the multi-protein complex and the intracellular
accumulation of b-catenin. Expression of Wnt10b in transgenic mice
increased bone mass and overexpression of Wnt7b and b-catenin
in C3H10T1/2 cells induced osteoblast differentiation. 34 However,
the exact mechanism by which Wnt signaling affects osteoblast
differentiation remains to be elucidated.
The canonical Wnt pathway is regulated by a soluble antagonists
that can be divided into two functional classes: dickkopf (DKK)
family and secreted frizzled-related proteins (sFRP). Members
of the DKK family bind to the LRP5/LRP6 component of the
Wnt receptor complex, while sFRP bind to Wnt proteins:
both result in a suppression of Wnt-signaling and a reduced
osteoblast function. To date, four Dkk proteins have been
identiﬁed in mammals 35 among which Dkk1 and Dkk2 have
been well characterized. DKK-1 has been shown to increase
RANKL/OPG ratio. For this reason elevated DKK1 levels may
enhance osteoclastogenesis. Wnt signaling in osteoblasts up-
regulates OPG expression and down-regulates RANKL expression, 36
suggesting a mechanism by which Wnt signaling in osteoblasts
indirectly regulates osteoclastogenesis. Data from several tumor
phenotypes suggest that DKK1 promotes osteolytic metastases,
and may facilitate the conversion of osteoblastic metastases to an
osteolytic phenotype. Prostate cancers usually express lower DKK1
levels compared with normal prostate tissue. In prostate cancer
cells DKK1 was found to block osteoblastic metastases without
affecting tumor growth, while inhibition of DKK1 in osteolytic
prostate cancer cells switched bone metastases from osteolytic to
osteoblastic Anti-DKK-1 therapy on bone metabolism and tumor
growth was recently experimented in mice: DKK-1-neutralizing
antibodies restored the BMD of the implanted myelomatous bone,
increased the numbers of osteocalcin-expressing osteoblasts and
reduced number of multinucleated TRAP-expressing osteoclasts.
Furthermore, the anti-DKK-1-treated mice showed reduced tumor
burden. 37 BHQ880, a fully human anti-DKK-1 neutralizing antibody,
promotes bone formation and inhibits tumor-induced osteolytic
disease in preclinical studies. 38
Taken together, these studies indicate WNT/DKK1 pathway is a
key regulator of bone remodelling in physiologic and pathologic
conditions. Target this pathway may potentially result in stimula-
tion of osteoblastogenesis and inhibition of osteoclastogenesis in
solid tumours.
Conclusion: Potential new targets and future perspective
In summary, a variety of novel targets in management of bone
disease are underway in preclinical and clinical testing phases. The
results from those in the advanced clinical phases are encouraging
and underlined the need to design large randomised clinical trials to
validate these results in the next future. Denosumab is the molecule
which is in the most advanced development phase, presently being
tested in Phase III trials. Further deﬁnition of the molecular and
cellular pathways involved into bone metastasis biology is ongoing
and it will likely lead to new and improved therapeutic strategies
in bone metastasis. For example Notch is emerged as an important
target in bone homeostasis. Mice knocked down for Notch lost the
ability to suppress bone resorption. Targeting Notch pathway by
gamma secretase inhibitors could represent in the next future a
feasible therapeutic strategy.
Moreover, many new therapeutic targets in bone metastases,
including TGF-b, Src, CXCR4, GPNMB and EGF-family ligands are
currently under pre clinical investigation.
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Targeting the bone by preventing skeletal related events (SREs)
and bone metastases has major clinical impact in improving survival
in bone metastatic patients and in preventing disease relapse in
adjuvant setting.
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